



1605  
(FEB)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Clark

Serial Number: 10/085,322

Confirmation No: 8526

Filed: February 28, 2002

Examiner: R. Zeman

Group Art Unit: 1645

For: "Use of Aminoglycosides to Treat Genetic Ophthalmic Diseases That Are Associated With Premature Termination Mutations"

COMMUNICATION

MS Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated January 4, 2006, please consider the following remarks.

REMARKS

Claims 1 – 10 are pending.

Claims 1 – 19 are subject to a restriction requirement under 35 U.S.C. §121 to one of the following inventions: Group I (Claims 1 – 10), drawn to methods of treating a patient with an ophthalmic disease caused by a mutation in the gene GLC1A utilizing an aminoglycoside antibiotic compound, or Group II (Claims 1 - 10), drawn to methods of treating a patient with an ophthalmic disease caused by a mutation in the gene CYP1B1 utilizing an aminoglycoside antibiotic compound.

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this date:

January 10, 2006  
Date  
Jeanne Burke  
Jeanne Burke